Strauch G, Perles P, Tresca J P, Letrait M, Broudic I, Delchambre J
Hôpital Cochin, Paris.
Contracept Fertil Sex. 1994 Nov;22(11):705-8.
Medrogestone (M) is a derivative of 17 methylprogesterone (P) used for P insufficiency at oral doses of 5 to 15 mg/day (D). We studied the ability of M to inhibit cyclic pituitary-ovarian activity when given at a dose of 10 mg/d from D4 to D24. Ten healthy Caucasian females, aged from 21 to 33, volunteered for an open 2 consecutive cycle study (cycle 1 = control, cycle 2 = M). At inclusion mean (+/- SD) cycle length was 28.6 +/- 1.9 D. Plasma LH, FSH, E2, P, were measured daily from D10 to D20 and at D22, 24, 26. During cycle 1, every subject showed an ovulatory pattern with mid cycle E2 peak (151-400 pg/ml), LH peak (12-59 mUI/ml) and luteal P rise (9.4-22.8 ng/ml). Under M ovulatory surges were suppressed in each of the 10 subjects and P remained below 0.8 ng/ml. These data show that in addition to its known progestomimetic effect, M is a potent ovulation inhibitor when given from D4 to D24 of the cycle.
甲地孕酮(M)是17 - 甲基孕酮(P)的衍生物,口服剂量为5至15毫克/天(D)时用于治疗孕酮不足。我们研究了从周期第4天(D4)至第24天(D24)给予10毫克/天剂量的甲地孕酮抑制垂体 - 卵巢周期性活动的能力。10名年龄在21至33岁之间的健康白种女性自愿参加了一项连续两个周期的开放性研究(第1周期 = 对照,第2周期 = 甲地孕酮)。入选时平均(±标准差)周期长度为28.6 ± 1.9天。从第10天(D10)至第20天以及在第22天、24天、26天每天测量血浆促黄体生成素(LH)、促卵泡生成素(FSH)、雌二醇(E2)、孕酮(P)。在第1周期,每个受试者都表现出排卵模式,有周期中期E2峰值(151 - 400皮克/毫升)、LH峰值(12 - 59毫国际单位/毫升)和黄体期孕酮升高(9.4 - 22.8纳克/毫升)。在甲地孕酮作用下,10名受试者中的每一个排卵高峰均受到抑制,且孕酮水平保持在0.8纳克/毫升以下。这些数据表明,除了已知的孕激素样作用外,在周期的第4天至第24天给予甲地孕酮时,它还是一种有效的排卵抑制剂。